• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

荷兰国家自发报告系统的信号:特征和监管行动。

Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions.

机构信息

Netherlands Pharmacovigilance Centre Lareb, 's Hertogenbosch, The Netherlands.

Utrecht University, Utrecht, The Netherlands.

出版信息

Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1115-1122. doi: 10.1002/pds.5246. Epub 2021 Apr 21.

DOI:10.1002/pds.5246
PMID:33840136
Abstract

PURPOSE

The aim of the study is to characterise safety signals based on the Dutch spontaneous reporting system (SRS) and to investigate the association between signal characteristics and Product Information (PI) update stratified by approval type: centrally authorised products (CAPs) versus nationally and decentralised authorised products (NAPs).

METHODS

This study evaluates the full cohort of signals disseminated from the Dutch SRS in the period from 2008 to 2017. Each retrieved signal was characterised on a number of aspects. The signal management process from signal generation to a potential PI update was analysed in four steps: (1) signal characterisation; (2) proposed actions by the Dutch national competent authority (NCA) for the signals; (3) presence of PI update (yes/no) and association with signal characteristics; (4) timing from the moment the signal was issued to PI update. For step 1-3 we stratified products in CAPs and NAPs.

RESULTS

Of all signals, 88.7% led to a proposed regulatory action by the NCA. Signals from the Dutch SRS for CAPs versus NAPs more often concerned biologicals, important medical events, class effects and shorter periods since marketing authorization. We detected PI updates for 26.2% of CAP signals and 61.3% of NAP signals.

CONCLUSIONS

The Dutch SRSs remains an important source of signals. There are some notable differences in the characteristics of signals for CAPs versus NAPs. Signals for NAPs more frequently led to PI updates.

摘要

目的

本研究旨在基于荷兰自发报告系统(SRS)对安全性信号进行特征描述,并调查信号特征与产品信息(PI)更新之间的关联,按批准类型分层:集中批准产品(CAPs)与国家和分散批准产品(NAPs)。

方法

本研究评估了 2008 年至 2017 年期间从荷兰 SRS 传播的完整信号队列。对每个检索到的信号进行了多个方面的特征描述。从信号生成到潜在 PI 更新的信号管理过程分为四个步骤进行分析:(1)信号特征描述;(2)荷兰国家主管当局(NCA)对信号提出的行动建议;(3)PI 更新的存在(是/否)以及与信号特征的关联;(4)从发出信号到 PI 更新的时间。在步骤 1-3 中,我们对 CAPs 和 NAPs 产品进行了分层。

结果

所有信号中,88.7%导致 NCA 提出监管行动建议。来自荷兰 SRS 的 CAP 信号与 NAP 信号更常涉及生物制品、重要医疗事件、类效应和自上市授权以来的较短时间。我们检测到 CAP 信号的 PI 更新率为 26.2%,NAP 信号的 PI 更新率为 61.3%。

结论

荷兰 SRS 仍然是信号的重要来源。CAP 与 NAP 的信号特征存在一些显著差异。NAP 的信号更频繁地导致 PI 更新。

相似文献

1
Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions.荷兰国家自发报告系统的信号:特征和监管行动。
Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1115-1122. doi: 10.1002/pds.5246. Epub 2021 Apr 21.
2
Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands.针对自发报告系统产生的药物安全信号所采取的行动:荷兰的回顾性研究
Int J Risk Saf Med. 2016 Aug 22;28(2):115-23. doi: 10.3233/JRS-160724.
3
Characteristics of drugs safety signals that predict safety related product information update.预测安全性相关产品信息更新的药物安全信号特征。
Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):789-796. doi: 10.1002/pds.4446. Epub 2018 May 24.
4
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.国家自发报告系统对检测致扭转型室性心动过速信号的贡献:ARITMO项目中出现的问题
Drug Saf. 2016 Jan;39(1):59-68. doi: 10.1007/s40264-015-0353-1.
5
Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.自发不良反应报告与电子健康记录在信号检测中的有益相互作用。
Drug Saf. 2015 Dec;38(12):1201-10. doi: 10.1007/s40264-015-0341-5.
6
The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.2010年至2015年期间,荷兰患者直接报告的药品不良反应对药物安全信号的贡献。
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):977-983. doi: 10.1002/pds.4236. Epub 2017 May 19.
7
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.评估患者向英国“黄卡计划”报告药物不良反应的情况:文献回顾、描述性和定性分析以及问卷调查。
Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200.
8
Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.监管批准时评估监管批准时第一批欧盟风险管理计划中的上市后安全性研究。
Drug Saf. 2009;32(12):1175-87. doi: 10.2165/11318980-000000000-00000.
9
The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.药物警戒数据库的不均衡性分析在安全监管行动中的作用:一项系统评价
Curr Drug Saf. 2015;10(3):234-50. doi: 10.2174/1574886310666150729112903.
10
A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.一种基于美国食品药品监督管理局监管行动和上市后不良事件报告的药物警戒信号系统。
Drug Saf. 2016 Jun;39(6):561-75. doi: 10.1007/s40264-016-0409-x.

引用本文的文献

1
An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records.利用电子健康记录加强潜在药物安全信号证据的创新方法。
J Med Syst. 2024 May 16;48(1):51. doi: 10.1007/s10916-024-02070-2.
2
Appeal for Increasing the Impact of Pharmacovigilance.呼吁提高药物警戒的影响力。
Drug Saf. 2024 Feb;47(2):113-116. doi: 10.1007/s40264-023-01375-4. Epub 2023 Dec 20.
3
Characteristics of drug safety alerts issued by the Spanish Medicines Agency.西班牙药品管理局发布的药品安全警报特征。
Front Pharmacol. 2023 Jan 30;14:1090707. doi: 10.3389/fphar.2023.1090707. eCollection 2023.